Abstract
Misoprostol versus Oxytocin in Prevention of Postpartum Hemorrhage
Highlights
Postpartum hemorrhage (PPH) continues to be the prime cause of maternal deaths predominantly in countries with limited resources [1]
Labor room, Department of Obstetrics and Gynecology, PGIMSR, ESIC during one year period from November 2009 to November 2010. 200 pregnant women were enrolled and were divided into two groups. Misoprostol and oxytocin both were effective in prevention of postpartum hemorrhage Though shivering and pyrexia are its specific side effect but they were transient; Misoprostol appears to be a safe, inexpensive, thermostable, long shelf life without special storage and effective uterotonic for use in rural and remote areas where parentral oxytocin may be unavailable
Mean hemoglobin value after 48 hour of delivery was comparable between misoprostol and oxytocin groups (10.939 g/dl and 11.011 g/dl) and no significant difference noted between the groups (p = 0.546)
Summary
Postpartum hemorrhage (PPH) continues to be the prime cause of maternal deaths predominantly in countries with limited resources [1]. PPH is mainly related to uterine atonicity WHO has recommended active management of the third stage of labor [2]. Execution of WHO guidelines in rural areas and in developing countries including India poses immense problems, as storage and parenteral administration of an oxytocic by a trained health worker is not feasible at many times in rural set up. Even lack of refrigeration for storing parenteral uterotonic drugs and non-availability of sterile syringes and needles, poses a major problem. There is a need for a safe, effective, affordable, thermo-stable, and nonparenteral uterotonic drug. Misoprostol is stable at room temperature, affordable and easy to administer. The present study was undertaken to assess the average blood loss in third stage of labor and find out the incidence of PPH in misoprostol group and oxytocin group.
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Journal of Andrology & Gynecology
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
